Personalized Vaccine for Cancer Immunotherapy

Exclusion Criteria

• •Patients with a diagnosis of triple-negative breast cancer.
• •Pregnant patients
• •Patients under age or over 70 years
• •Patients diagnosed with autoimmune diseases
• •The patient has a Karnofsky lower than 70% or an ECOG higher than 1.
• •Patients who have received some therapy as a treatment for their tumor pathology (radiotherapy, chemotherapy, immunotherapy, or gene therapy).
• •Active autoimmune disease requiring treatment or a history of autoimmune disease that could be exacerbated by treatment. Patients with endocrine disease controlled by replacement therapy, including thyroid disease, adrenal disease, and vitiligo, can be included.
• •Presence of a chronic or acute infection, such as HIV, viral hepatitis, or tuberculosis, before or after signing the informed consent.
• •Use of immunosuppressants within 4 weeks before the trial (e.g., corticosteroids), such as azathioprine, prednisone, or cyclosporine A. The use of local steroids (topical, nasal, or inhaled) may be acceptable.
• •Clinically significant cardiomyopathy, which requires treatment.
• •Splenectomized patients.
• •Patients who do not receive the neoadjuvant chemotherapy regimen with Doxorubicin and cyclophosphamide for three cycles or receive some other type of complementary therapy such as taxanes.